Kirsi Kainulainen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Kirsi Kainulainen has a total of 35 co-authors. Here are the top co-authors by number of shared publications:
- Sanna Pasonen-Seppänen
Institute of Biomedicine, School of Medicine, University of Eastern Finland, Kuopio, Finland
3 shared publications - Kirsi Ketola
Institute of Biomedicine, University of Eastern Finland, 70210, Kuopio, Finland
2 shared publications - Piia Takabe
Institute of Biomedicine, School of Medicine, University of Eastern Finland, Kuopio, Finland
2 shared publications - Anna-Liisa Levonen
A.I. Virtanen Institute for Molecular Sciences, University of Eastern Finland, Kuopio, Neulaniementie 2, 70211, Finland
1 shared publication - Antti Poso
University of Eastern Finland
1 shared publication - Ashik Jawahar Deen
Department of Protein Science, Royal Institute of Technology, Stockholm, Sweden
1 shared publication
Latest Publications
- Open Access
- 21 August 2024
- Published by Taylor & Francis in OncoImmunology
- Vol. 13 (1) , 2393442
Secreted factors from M1 macrophages drive prostate cancer stem cell plasticity by upregulating NANOG, SOX2 , and CD44 through NFκB-signaling
1. Tumor microenvironment (TME) exhibits high heterogeneity with the composition of different immune cells, cancer-associated fibroblasts, tumor cells, and extracellular matrix changing during tumo...
- 21 August 2024
- Published by Taylor & Francis in OncoImmunology
- Vol. 13 (1) , 2393442
Open AccessSecreted factors from M1 macrophages drive prostate cancer stem cell plasticity by upregulating NANOG, SOX2 , and CD44 through NFκB-signaling
1. Tumor microenvironment (TME) exhibits high heterogeneity with the composition of different immune cells, cancer-associated fibroblasts, tumor cells, and extracellular matrix changing during tumo...
- Open Access
Oncogenic KEAP1 mutations activate TRAF2-NFκB signaling to prevent apoptosis in lung cancer cells
The Kelch-like ECH-associated protein 1 (KEAP1) – Nuclear factor erythroid 2-related factor 2 (NRF2) pathway is the major transcriptional stress response system in cells against oxidative and electrophilic stress. NRF2 is frequently constitutively active in many cancers, rendering the cells resistant to chemo- and radiotherapy. Loss-of-function (LOF) mutations in the repressor protein KEAP1 are common in non-small cell lung cancer, particularly adenocarcinoma. While the mutations can occur throughout the gene, they are enriched in certain areas, indicating that these may have unique functional importance. In this study, we show that in the GSEA analysis of TCGA lung adenocarcinoma RNA-seq data, the KEAP1 mutations in R320 and R470 were associated with enhanced Tumor Necrosis Factor alpha (TNFα) – Nuclear Factor kappa subunit B (NFκB) signaling as well as MYC and MTORC1 pathways. To address the functional role of these hotspot mutations, affinity purification and mass spectrometry (AP-MS) analysis of wild type (wt) KEAP1 and the mutants was employed to interrogate differences in the protein interactome. We identified TNF receptor associated factor 2 (TRAF2) as a putative protein interaction partner. Both mutant KEAP1 forms showed increased interaction with TRAF2 and other anti-apoptotic proteins, suggesting that apoptosis signalling could be affected by the protein interactions. A549 lung adenocarcinoma cells overexpressing mutant KEAP1 showed high TRAF2-mediated NFκB activity and increased protection against apoptosis, XIAP being one of the key proteins involved in anti-apoptotic signalling. To conclude, KEAP1 R320Q and R470C and its interaction with TRAF2 leads to activation of NFκB pathway, thereby protecting against apoptosis.
Open AccessOncogenic KEAP1 mutations activate TRAF2-NFκB signaling to prevent apoptosis in lung cancer cells
The Kelch-like ECH-associated protein 1 (KEAP1) – Nuclear factor erythroid 2-related factor 2 (NRF2) pathway is the major transcriptional stress response system in cells against oxidative and electrophilic stress. NRF2 is frequently constitutively active in many cancers, rendering the cells resistant to chemo- and radiotherapy. Loss-of-function (LOF) mutations in the repressor protein KEAP1 are common in non-small cell lung cancer, particularly adenocarcinoma. While the mutations can occur throughout the gene, they are enriched in certain areas, indicating that these may have unique functional importance. In this study, we show that in the GSEA analysis of TCGA lung adenocarcinoma RNA-seq data, the KEAP1 mutations in R320 and R470 were associated with enhanced Tumor Necrosis Factor alpha (TNFα) – Nuclear Factor kappa subunit B (NFκB) signaling as well as MYC and MTORC1 pathways. To address the functional role of these hotspot mutations, affinity purification and mass spectrometry (AP-MS) analysis of wild type (wt) KEAP1 and the mutants was employed to interrogate differences in the protein interactome. We identified TNF receptor associated factor 2 (TRAF2) as a putative protein interaction partner. Both mutant KEAP1 forms showed increased interaction with TRAF2 and other anti-apoptotic proteins, suggesting that apoptosis signalling could be affected by the protein interactions. A549 lung adenocarcinoma cells overexpressing mutant KEAP1 showed high TRAF2-mediated NFκB activity and increased protection against apoptosis, XIAP being one of the key proteins involved in anti-apoptotic signalling. To conclude, KEAP1 R320Q and R470C and its interaction with TRAF2 leads to activation of NFκB pathway, thereby protecting against apoptosis.
- Open Access
- 14 May 2022
- Published by Elsevier in Journal of Investigative Dermatology
- Vol. 142 (11) , 3041-3051.e10
M1 Macrophages Induce Protumor Inflammation in Melanoma Cells through TNFR–NF-κB Signaling
- 14 May 2022
- Published by Elsevier in Journal of Investigative Dermatology
- Vol. 142 (11) , 3041-3051.e10
Open AccessM1 Macrophages Induce Protumor Inflammation in Melanoma Cells through TNFR–NF-κB Signaling